DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for neuronal ceroid lipofuscinosis 8 — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleNeuronal ceroid lipofuscinosis 8 maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for neuronal ceroid lipofuscinosis 8 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
CLN8 transmembrane ER and ERGIC protein (CLN8) — CLN8 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet coadrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 9TKA · 2.7 Å · ligand COENZYME A (COA). Experimental structure, not a prediction.
What the evidence adds up to
The abstracts describe neuronal ceroid lipofuscinosis (NCL) as a group of inherited, progressive neurodegenerative disorders, often called Batten disease, that are fatal and autosomal recessive. Clinical features across subtypes include visual loss, seizures, deterioration of motor and cognitive function, and early death. At autopsy, massive neuronal loss and characteristic storage material in remaining neurons are found. By 2003, gene products for six of eight known NCL forms had been discovered; by 2016, 13 genetic forms (CLN1 to CLN14) had been identified. The CLN genes are thought to function in the endosomal-lysosomal system, with neuron-specific roles, and neuronal death is attributed to increased apoptosis and altered autophagy.
Several therapeutic modalities are in development, including enzyme replacement therapy, gene therapy, stem cell therapy, small molecule pharmacotherapy, and diet modifications. Some therapies have shown measures of success in pre-clinical studies and progressed to human clinical trials. However, the abstracts report no concrete survival or response rate numbers from any completed trial. The blood-brain barrier is noted as a major obstacle to central nervous system access, and the need to remove accumulated debris throughout the CNS is described as a significant challenge. No single drug is named in any of the provided abstracts as having demonstrated efficacy in patients.
The abstracts do not provide data from any completed clinical trial for NCL8 specifically, nor do they report any quantitative outcomes such as survival or response rates. The 2003 review stresses the need to characterise clinical progression and identify quantifiable endpoints for future trials. What remains missing is evidence from adequately powered, controlled clinical trials that report survival or functional outcomes, and the identification of biomarkers or endpoints that can reliably measure disease modification in NCL8.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Current Opinion in Neurology · 2003 · 98 citations
Progress towards understanding the neurobiology of Batten disease or neuronal ceroid lipofuscinosis
AbstractPURPOSE OF REVIEW: The identification of genes mutated in the neuronal ceroid lipofuscinoses has accelerated research into the mechanisms that underlie these fatal autosomal recessive storage disorders, which are often referred to as Batten disease. This review summarizes progress in this field since October 2001, describing advances in cell biology, the characterization of new animal models of neuronal ceroid lipofuscinosis, and the impact of novel methodology to reveal insights into its pathogenesis. RECENT FINDINGS: Gene products for six of the eight forms of neuronal ceroid lipofuscinosis have now been discovered, and concerted efforts are underway to understand the normal biology of each gene product and how this may be altered by mutation. Several lines of evidence point to functions for the CLN genes in the endosomal-lysosomal system, and suggest neuron-specific roles for these proteins. Indeed, a requirement for appropriate protein trafficking within neurons may explain the profound and selective effects of these disorders upon the central nervous system. The development of mouse and large animal models has enabled comparative studies of the progressive effects of disease, including characterization by morphological and biochemical means supplemented by metabonomic and microarray techniques. SUMMARY: Insights into disease mechanisms are building a detailed profile of the impact of neuronal ceroid lipofuscinosis upon the brain. With the eventual aim of developing successful therapeutic strategies, it will be equally important to characterize the clinical progression of the disorder, and to identify quantifiable endpoints that can ultimately be used in clinical trials.
Current Opinion in Neurology · 2003 · 82 citations
Progress towards understanding the neurobiology of Batten disease or neuronal ceroid lipofuscinosis
AbstractPurpose of review The identification of genes mutated in the neuronal ceroid lipofuscinoses has accelerated research into the mechanisms that underlie these fatal autosomal recessive storage disorders, which are often referred to as Batten disease. This review summarizes progress in this field since October 2001, describing advances in cell biology, the characterization of new animal models of neuronal ceroid lipofuscinosis, and the impact of novel methodology to reveal insights into its pathogenesis. Recent findings Gene products for six of the eight forms of neuronal ceroid lipofuscinosis have now been discovered, and concerted efforts are underway to understand the normal biology of each gene product and how this may be altered by mutation. Several lines of evidence point to functions for the CLN genes in the endosomal-lysosomal system, and suggest neuron-specific roles for these proteins. Indeed, a requirement for appropriate protein trafficking within neurons may explain the profound and selective effects of these disorders upon the central nervous system. The development of mouse and large animal models has enabled comparative studies of the progressive effects of disease, including characterization by morphological and biochemical means supplemented by metabonomic and microarray techniques. Summary Insights into disease mechanisms are building a detailed profile of the impact of neuronal ceroid lipofuscinosis upon the brain. With the eventual aim of developing successful therapeutic strategies, it will be equally important to characterize the clinical progression of the disorder, and to identify quantifiable endpoints that can ultimately be used in clinical trials.
Oxford University Press eBooks · 2016 · 10 citations
Neuronal Ceroid Lipofuscinoses
AbstractNeuronal ceroid lipofuscinoses (NCLs) are inherited neurodegenerative disorders beginning mainly in childhood, rarely in adults. They are characterized by the accumulation of autofluorescent lipopigments in brain, especially in neurons. Their clinical heterogeneity is now explained by the huge number of genes (from CLN1 to CLN14) involved in their pathogenesis. Their diagnosis is possible using enzymatic tests and/or direct sequencing of the corresponding genes. Different therapeutic approaches are in development for these diseases such as enzyme replacement therapy or gene transfer.
Expert Opinion on Orphan Drugs · 2013 · 9 citations
Advances in the treatment of neuronal ceroid lipofuscinosis
AbstractIntroduction: Neuronal ceroid lipofuscinoses (NCL) represent a class of neurodegenerative disorders typically characterized by cognitive and visual impairment, seizures, deterioration of motor skills and early mortality. There has been increased interest in developing therapies directed towards slowing the progression, and possibly preventing and reversing the impact of these disorders. Despite many challenges, including the presence of the blood–brain barrier which prevents access to the central nervous system (CNS) and the need to markedly remove accumulated debris throughout the CNS, many treatment modalities have been proposed, including enzyme replacement therapy, gene therapy, stem cell therapy, small molecule pharmacotherapy and diet modifications. Some therapies have demonstrated measures of success, and these have progressed to human clinical trials. Continued development of current therapies and discovery of newer approaches will be essential for success. Areas covered: The reader will be introduced to the 14 known NCLs, the current approach to therapies, the evidence for efficacy and the challenges to success both at the pre-clinical and clinical stage. This review corresponds to the literatures covering the years from 1968 to mid-2013. Expert opinion: Much progress has been made in the classification of this family of neurologic diseases, including the genetic basis and functional outcomes which have led to the evaluation of several therapeutic interventions. These include enzyme replacement therapy, gene therapy, stem cell therapy, small molecule pharmacotherapy and diet modifications, each of which has associated pros and cons. Successful therapies in the future may necessitate the combination of two or more therapeutic modalities.
Journal of Pediatric Biochemistry · 2016 · 3 citations
The Neuronal Ceroid Lipofuscinoses: A Case-Based Overview
AbstractThe neuronal ceroid lipofuscinoses (NCLs) are a heterogeneous group of inherited, progressive neurodegenerative diseases. Manifestations may begin between the neonatal period and young adulthood, depending on the various subtypes. The different phenotypes are similar and include visual loss, seizures, loss of motor and cognitive function, and early death. At autopsy, there is massive neuronal loss with characteristic storage in the remaining neurons. Neurons appear to die because of increased rates of apoptosis and altered autophagy as occurs in lysosomal storage diseases. A total of 13 neuronal ceroid lipofuscinoses (CLN) genetic forms have been identified so far (CLN type 1–14). In the present review, we propose a classification scheme of the major forms and report the case of a familial recurrence of NCL type 10, with a mutation in the CLN10 gene coding for the cathepsin D protein.
Neuronal Ceroid Lipofuscinoses: Many Players, and More to Come
AbstractThe neuronal ceroid lipofuscinoses (NCL) are the most common group of progressive neurodegenerative diseases of childhood. The overall clinical features are highly similar regardless of the age at disease manifestation, the extent and shape of abnormally stored cytosomes and the severity of clinical course, and are generally characterized by failure and regression of psychomotor development, impaired vision, seizures and fatal outcome. The expanding array of genetic etiologies and disease-associated mutations in NCL provide the basis for the heterogeneity of these clinical conditions and are the focus of this review. Less understood are the pathogenic mechanisms, but common themes and molecular pathways are now emerging and new players are expected to come into the scene of NCL.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
